ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Maxpro Capital Acquisition Corporation

Maxpro Capital Acquisition Corporation (JMAC)

10,81
0,00
(0,00%)
Fermé 04 Février 10:00PM
0,00
0,00
(0,00%)
Après les heures de négociation: -

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

Dernier
10,81
Prix Achat
10,80
Prix Vente
12,05
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Clôture Veille
10,81
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume moyen (3 m)
-
Volume financier
-
VWAP
-

JMAC Dernières nouvelles

Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq

FOSTER CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates...

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Taipei City, Jan. 13, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”) announced today that its sponsor, MP One Investment LLC (the...

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

TAIPEI CITY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”), announced today that its sponsor, MP One Investment LLC (the...

Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations

FOSTER CITY, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: JMAC), an innovative biopharmaceutical company committed to the discovery and development of mono- and...

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

TAIPEI CITY, Oct. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”) announced today that its sponsor, MP One Investment LLC (the...

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

Taipei City, Oct. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”), announced today that its sponsor, MP One Investment LLC (the...

Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp.

– Transaction values Apollomics at pre-money equity value of $899 million– Apollomics is a late-stage clinical biopharmaceutical company developing innovative product candidates for large, unmet...

Maxpro Capital Acquisition Corp. Announces the Separate Trading of Its Class A Common Stock and Warrants

TAIPEI CITY, Nov. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (“Maxpro” or the “Company”), a blank check company formed for the purpose of effecting a...

Maxpro Capital Acquisition Corp. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option

Taipei City, Oct. 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (the “Company”), a Taiwan based SPAC, today announced the closing of its initial public...

Maxpro Capital Acquisition Corp. Announces Pricing of $90,000,000 Initial Public Offering

Taipei City, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (the “Company”), a Taiwan based SPAC, announced today that it priced its initial public...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

JMAC - Frequently Asked Questions (FAQ)

What is the current Maxpro Capital Acquisition share price?
The current share price of Maxpro Capital Acquisition is US$ 10,81
What is the 1 year trading range for Maxpro Capital Acquisition share price?
Maxpro Capital Acquisition has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
IVVDInvivyd Inc
US$ 1,055
(194,94%)
448,53M
HCWBHCW Biologics Inc
US$ 0,6265
(125,20%)
344,42M
UOKAMDJM Ltd
US$ 0,2293
(76,38%)
354,09M
GHRSGH Research PLC
US$ 17,9991
(69,80%)
10,31M
WHLRLWheeler Real Estate Investment Trust Inc
US$ 234,64
(61,82%)
392
CYNCYNGN Inc
US$ 0,1169
(-56,70%)
75,52M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,1943
(-54,61%)
327,95M
VIRXViracta Therapeutics Inc
US$ 0,0741
(-51,09%)
9,37M
BOWNUBowen Acquisition Corporation
US$ 3,39
(-49,55%)
17,28k
PITAHeramba Electric PLC
US$ 0,503
(-44,11%)
1,37M
IVVDInvivyd Inc
US$ 1,055
(194,94%)
448,53M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,0462
(27,98%)
434,24M
NVDANVIDIA Corporation
US$ 116,66
(-2,84%)
371,47M
UOKAMDJM Ltd
US$ 0,2293
(76,38%)
354,09M
HCWBHCW Biologics Inc
US$ 0,6265
(125,20%)
344,42M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock